Search results

In general, conduction velocity is supposed to increase with higher activation threshold/higher force output and thus is associated with greater membrane excitability. However the difference isn't always appreciable at the force outputs used in the study (20% MVC). The FM patients were suitable...

Long term, I suspect the efficacy of the second dose at both intervals is probably the same. In the short term (3 months after the second dose), there is suggestive evidence that the 12 week interval could lead to higher effiacy. The second dose of the AZ vaccine doesn't have the same function...

Here are some correlates of increased conduction velocity: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1192232/?page=8 (decreased rise time, relaxation time and increased twitch torque) I still don't have access to the aforementioned ME/CFS study...

Note, the sample size isn't huge, so there is some uncertainty, but the efficacy against any PCR positive result (asymptomatic + symptomatic) was 77%. (for the Pfizer vaccine)

I'd expect the effect to be similar. I can't remember the link to the video, unfortunately.

Vaccine efficacy in aged care in the UK https://www.medrxiv.org/content/10.1101/2021.03.26.21254391v1.full.pdf Around 62% efficacy against symptomatic infection at 35-48 days, after one dose of either AZ (67% of the vaccinated cohort received this) or Pfizer (33% received this). (median age 86...

I'd argue, yes, the question is how well? The AZ vaccine was at least in the 50% range for efficacy against asymptomatic + symptomatic infection (at least against the UK/ancestral variants). The Pfizer vaccine was in the 80% range, though the data is not as robust. I's also argue that a true...

I can't guess the reason. The adenovirus based vaccines aren't significantly less 'reactogenic' than the mRNA vaccines.

There are "traditional" vaccines too, Novavax which is a subunit vaccine and CoronaVac from Sinovac, which is a inactivated virus vaccine. So the "this is new technology" argument only extends so far...

One thing I'd like to point out is that inhibition of α-ketoglutarate dehydrogenase inhibits ROS production, thus preventing this particular step in the cycle leading to a feedback loop involving excessive ROS. https://www.jneurosci.org/content/24/36/7779.short

I'd expect both to be worse after the second dose.

The bigger worry is what is going to emerge in 6-9 months time. One thing that annoys me is the media keeps talking about the possibility of annual 'booster' shots. But they aren't 'booster' shots at all. Booster shots are an additional dosage of the same vaccine. If we need annual shots, it is...

Of course referencing a trial of CBT/GET as the "prevailing view" of ME/CFS means that this treatment does imply it is a psychiatric disorder. This contradicts the claims from certain prominent UK people who keep insisting that just because CBT is used as a treatment doesn't necessarily mean...

These 100% efficacy claims against hospitalisation/death are not genereralisable due to limited sample size and participation bias. We know from UK/Israel data that vaccinated individuals can still die of COVID19.

Just seems like the latest in COVID apologists. 'I mean yes, COVID was a violent misogynist when he was young, but COVID is a different person now! You'd like him if you just gave him a chance and got to know him better!'

But it's not just clotting, it is a rare autoimmune reaction to those clots that is the primary cause for concern. I don't buy the poor technique argument. But I also don't believe this issue is specific to the AZ vaccine.

https://www.washingtonpost.com/world/astrazeneca-oxford-vaccine-concerns/2021/03/23/2f931d34-8bc3-11eb-a33e-da28941cb9ac_story.html

The NIAID is accusing them of cherry-picking their data, to which AZ replied "nah mate we double checked and it's all good, no worries!"* *It's possible the paraphrasing process may suggest a different nationality to those who made the comment

https://www.nih.gov/news-events/news-releases/niaid-statement-astrazeneca-vaccine This is why we can't have nice things! edit - Update: https://www.astrazeneca.com/media-centre/press-releases/2021/update-following-statement-by-niaid-on-azd1222-us-phase-iii-trial-data.html

If your clients have such markers, they probably have something else going in addition to, or instead of ME/CFS. In over 30 years of research, with over 50+ studies on cortisol patterns or related neuroendocrine systems, researchers have only found equivocal results. This should be a clue...